The Mouse Monoclonal anti-APOA1 antibody (Clone 057-16001) (ABIN263694) specifically detects APOA1 in RIA and EIA.
The antibody is reactive with Human samples.
This antibody recognizes Apolipoprotein A I. This product does not cross react with Apo AII or Apo B in competitive RIA.Aff. Const.:1 x 10e7 L/m (determined by RIA followed by Scatchard plot analysis)
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Concentration
5.0 mg/mL (OD280nm, E0.1% = 1.4)
Buffer
10 mM Phosphate, pH 7.4 containing 150 mM Sodium Chloride and 0.09 % Sodium Azide
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
4 °C/-20 °C
Storage Comment
Store the antibody undiluted at 2-8 °C for one week or (in aliquots) at -40 °C for longer. If aliquoted for long term storage, fill volume should be equal to or greater than 50% of thenominal fill volume of the vial used. Avoid repeated freezing and thawing. Shelf life: one year from despatch.
Expiry Date
12 months
Target
APOA1
(Apolipoprotein A-I (APOA1))
Alternative Name
Apolipoprotein A I (APO AI)
Background
Apolipoprotein A I promotes cholesterol efflux from tissues to the liver for excretion. Apolipoprotein A I is the major protein component of high density lipoprotein (HDL) in the plasma. Synthesized in the liver and small intestine, it consists of two identical chains of 77 amino acids, an 18 amino acid signal peptide is removed co-translationally and a 6 amino acid propeptide is cleaved post-translationally. Apolipoprotein A I is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. Defects in the Apolipoprotein A I gene are associated with HDL deficiency and Tangier disease. The therapeutic potential of apoA-I has been recently assessed in patients with acute coronary syndromes, using a recombinant form of a naturally occurring variant of apoA-I. The availability of recombinant normal apoA-I should facilitate further investigation into the potential usefulness of apoA-I in preventing atherosclerotic vascular diseases.Synonyms: APOA1, Apo-AI, ApoA-I, ApoAI